{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-003789","form_type":"8-K","ticker":"DERM","cik":"0001867066","company_name":"Journey Medical Corp","filed_at":"2022-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.941991+00:00","generated_at":"2026-06-27T18:24:37.001373+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Journey Medical acquires VYNE's MST franchise for $20M upfront; credit facility expanded to $30M","bullets":["Acquired AMZEEQ, ZILXI, FCD105, and MST platform for $20M upfront plus $5M at one year; contingent milestones up to $450M.","Products generated ~$4M net sales in Q3 2021; portfolio now includes nine marketed dermatology products.","Credit facility with East West Bank expanded to $30M: $10M revolver + $20M term loan to finance acquisition and working capital.","Journey substituted as plaintiff in patent litigation against Padagis over Amzeeq; trial set for July 2023, stay until Dec 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-003789","json":"https://secwatch.observer/filing/0001104659-22-003789.json","markdown":"https://secwatch.observer/filing/0001104659-22-003789.md","text":"https://secwatch.observer/filing/0001104659-22-003789.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867066/000110465922003789/0001104659-22-003789-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867066/000110465922003789/tm222871d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T18:24:37.001373+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}